Prospective evaluation of blood myeloid derived suppressor cells as a biomarker of cancer in dogs

Archive ouverte

Nadal, Clémence | Béguin, Jérémy | Benchekroun, Ghita | Le Roux, Delphine

Edité par CCSD -

International audience. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immature cells predominantly found in the bone marrow. In healthy mice, these cells represent about 0.5% of blood cells and less than 4% of splenocytes [1,2]. However, studies have shown that MDSCs accumulate in secondary lymphoid organs in many pathological conditions. In the particular case of cancer, MDSCs accumulate in the blood, spleen, lymph nodes and in the tumor microenvironment, where they suppress the immune response through various mechanisms, leading to tumour escape [3].The aim of this study was to compare the percentage of circulating MDSCs in dogs with cancer (group 1), healthy dogs (group 2) and dogs with non-neoplastic diseases (group 3). For this, peripheral blood mononuclear cells were isolated, labeled with CD11b, CD14, MHCII antibodies and quantified by flow cytometry. Percentages of circulating MDSCs were calculated among the CD11b+ cells. Thirty dogs were included in group 1, 30 dogs in group 2 and 15 in group 3. The MDSCs median [IQR] value was 20.9% [10.8;35.8] in group 1, 2.9% [1.0;9.5] in group 2, and 15.9% [7.1;31.8] in group 3. Group 1 had significantly higher percentage of MDSCs compared to group 2 (p<0.01). There was no significant difference between group 1 and 3 (p=0.36).Our results showed a significant increase of circulating MDSCs in dogs with cancer compared to healthy dogs. Therefore, MDSCs could be an interesting biomarker for the diagnosis and follow-up of dogs with cancer. However non-neoplastic diseases were also associated with an elevated percentage of MDSCs. Thus, further studies are needed in order to assess the percentage of MDSCs as a specific tool for the early diagnosis of cancer and metastasis.[1] D.I. Gabrilovich, S. Nagaraj, Nat Rev Immunol 2009 ; [2] P. Trikha, W. Carson, Biochim Biophys Acta 2014. [3] K.H. Parker, et al., Adv Cancer Res 2015.

Consulter en ligne

Suggestions

Du même auteur

Prospective evaluation of blood myeloid derived suppressor cells as a biomarker of cancer in dogs

Archive ouverte | Béguin, Jérémy | CCSD

International audience. IntroductionMyeloid-derived suppressor cells (MDSCs) are key players in immunosuppressive mechanisms that lead to tumor escape and metastasis formation, both in human patients and murine mode...

Blood biomarkers for canine cancer, from human to veterinary oncology

Archive ouverte | Colombe, Philippe | CCSD

International audience. In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify ...

Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases

Archive ouverte | Lecot, Lorris | CCSD

International audience. Background: Myeloma‐related disorders (MRDs) are rare and poorly documented neoplasms of cats. Hypothesis/Objectives: To describe clinical, clinicopathologic, and imaging findings, response t...

Chargement des enrichissements...